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Abstract
Background: Antigenic chimeric viruses have previously been generated in which the structural
genes of recombinant dengue virus type 4 (rDEN4) have been replaced with those derived from
DEN2 or DEN3. Two vaccine candidates were identified, rDEN2/4Δ30(ME) and rDEN3/4Δ30(ME),
which contain the membrane (M) precursor and envelope (E) genes of DEN2 and DEN3,
respectively, and a 30 nucleotide deletion (Δ30) in the 3' untranslated region of the DEN4
backbone. Based on the promising preclinical phenotypes of these viruses and the safety and
immunogenicity of rDEN2/4Δ30(ME) in humans, we now describe the generation of a panel of four
antigenic chimeric DEN4 viruses using either the capsid (C), M, and E (CME) or ME structural genes
of DEN1 Puerto Rico/94 strain.
Results: Four antigenic chimeric viruses were generated and found to replicate efficiently in Vero
cells: rDEN1/4(CME), rDEN1/4Δ30(CME), rDEN1/4(ME), and rDEN1/4Δ30(ME). With the
exception of rDEN1/4(ME), each chimeric virus was significantly attenuated in a SCID-HuH-7
mouse xenograft model with a 25-fold or greater reduction in replication compared to wild type
DEN1. In rhesus monkeys, only chimeric viruses with the Δ30 mutation appeared to be attenuated
as measured by duration and magnitude of viremia. rDEN1/4Δ30(CME) appeared over-attenuated
since it failed to induce detectable neutralizing antibody and did not confer protection from wild
type DEN1 challenge. In contrast, rDEN1/4Δ30(ME) induced 66% seroconversion and protection
from DEN1 challenge. Presence of the Δ30 mutation conferred a significant restriction in mosquito
infectivity upon rDEN1/4Δ30(ME) which was shown to be non-infectious for Aedes aegypti fed an
infectious bloodmeal.
Conclusion: The attenuation phenotype in SCID-HuH-7 mice, rhesus monkeys, and mosquitoes
and the protective immunity observed in rhesus monkeys suggest that rDEN1/4Δ30(ME) should be
considered for evaluation in a clinical trial.
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Background
The dengue (DEN) viruses are members of the Flaviviridae
family and contain a single-stranded positive-sense RNA
genome [1]. A single viral polypeptide is cotranslationally
processed by viral and cellular proteases generating three
structural proteins (capsid C, membrane M, and envelope
E) and at least seven non-structural (NS) proteins. The
genome organization of the DEN viruses is 5'-UTR-C-
prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-UTR-3'
(UTR – untranslated region, prM – membrane precursor).
Four dengue virus serotypes (DEN1, DEN2, DEN3, and
DEN4) circulate in tropical and subtropical regions of the
world inhabited by more than 2.5 billion people. There
are an estimated 50 million dengue infections annually
and hundreds of thousands of cases of dengue hemor-
rhagic fever (DHF), with children bearing much of the dis-
ease burden [2,3]. The increase in both the incidence and
severity of disease caused by the four DEN serotypes over
the past several decades has been well documented [4].
DEN viruses are maintained in a life cycle of transmission
from mosquito to human to mosquito with no other
apparent viral reservoir participating in this life cycle in
urban settings [5].
An economical vaccine that prevents disease caused by the
DEN viruses has become a global public health priority.
The cost-effectiveness, safety, and long-term efficacy asso-
ciated with the live attenuated vaccine against yellow fever
(YF) virus, another mosquito-borne flavivirus, serves as a
model for the feasibility of developing a live attenuated
DEN virus vaccine [6]. We have employed two strategies
for generating live attenuated vaccine candidates against
each serotype which can then be combined into a tetrava-
lent vaccine [7,8]. First, reverse genetics has been used to
introduce an attenuating 30 nucleotide deletion (Δ30)
mutation into the 3' untranslated region of cDNA clones
of each DEN serotype [9-12]. In initial studies, the
rDEN4Δ30 vaccine candidate was found to be attenuated
in rhesus monkeys and phase I/II clinical trials in humans
have demonstrated that virus infection results in low
viremia, is strongly immunogenic, and exhibits minimal
reactogenicity without serious adverse events [9,13]. The
rDEN1Δ30 vaccine candidate, which was also attenuated
in rhesus monkeys, has been found to share a similar set
of properties in clinical trials as that observed for
rDEN4Δ30; low viremia, strong immunogenicity, and
minimal reactogenicity [14]. Importantly, both vaccines
are highly immunogenic at a dose of 103 PFU/vaccinee
indicating the feasibility for manufacture at low cost.
Unfortunately, the rDEN2Δ30 and rDEN3Δ30 viruses
were found to not be attenuated in rhesus monkeys
[11,12]. Therefore, a second strategy for vaccine develop-
ment was employed to develop the DEN2 and DEN3
components for the tetravalent DEN vaccine. This strategy
involved the generation of antigenic chimeric viruses by
replacement of the M and E structural proteins (ME) of
the attenuated rDEN4Δ30 vaccine candidate with those
from DEN2 or DEN3 yielding the rDEN2/4Δ30 and
rDEN3/4Δ30 vaccine candidates, respectively [11,15].
During these studies it was found that antigenic chimeri-
zation of DEN2 or DEN3 with DEN4 yielded an attenu-
ated virus. The rDEN2/4Δ30 vaccine virus has been tested
in humans and appears safe, infectious, and strongly
immunogenic at a dose of 103 PFU/vaccinee [16], while
clinical evaluation of the rDEN3/4Δ30 virus is ongoing.
In this report, we extend the previous studies of rDEN2/4
and rDEN3/4 chimeric viruses by describing the genera-
tion of a panel of rDEN1/4 antigenic chimeric viruses
using either the CME or ME structural genes of DEN1
Puerto Rico/94 on a DEN4 genetic background with and
without the Δ30 mutation. The goal of this study was two-
fold: to identify a suitable back-up vaccine candidate for
the rDEN1Δ30 virus and to determine if DEN1, like DEN2
and DEN3, could be attenuated by chimerization with
DEN4. Four antigenic chimeric viruses were generated
and found to replicate efficiently in Vero cells: rDEN1/
4(CME), rDEN1/4Δ30(CME), rDEN1/4(ME), and
rDEN1/4Δ30(ME). The level of replication of these
viruses was compared to that of wild type DEN1 or DEN4
in a SCID-HuH-7 mouse xenograft model, in rhesus mon-
keys, and in Aedes aegypti mosquitoes, and their immuno-
genicity and efficacy was evaluated in rhesus monkeys.
Results
Construction and recovery of chimeric DEN1 vaccine 
candidates
The chimerization of the structural genes of DEN1 Puerto
Rico/94 with DEN4 was performed in a manner similar to
methods used to construct the rDEN2/4 and rDEN3/4 chi-
meric viruses (Figure 1) [11,15]. Construction of a stable
p4-D1-CME cDNA clone required the addition of a linker
sequence between the E and NS1 genes as had been
observed for the construction of the rDEN3/4 chimeric
cDNA clones [11]. A total of four chimeric viruses were
generated with either two (ME) or three (CME) DEN1
structural genes in the DEN4 background with or without
the Δ30 mutation in the DEN4 3' UTR. These chimeric
viruses are referred to as rDEN1/4(CME), rDEN1/
4Δ30(CME), rDEN1/4(ME), and rDEN1/4Δ30(ME).
Recombinant viruses were recovered in C6/36 cells and
then were adapted to Vero cells by serial passage. Follow-
ing adaptation, the viruses were biologically cloned by ter-
minal dilution in Vero cells, and the complete nucleotide
sequence of each chimeric virus was determined (Table
1). As expected, adventitious mutations were detected in
the virus populations with each virus containing at least
one amino acid change in NS4B, which is a previously
identified locus for accumulation of mutations that
enhance replication in Vero cells [17].Virology Journal 2007, 4:23 http://www.virologyj.com/content/4/1/23
Page 3 of 11
(page number not for citation purposes)
Chimeric viruses were assessed for replication in Vero
cells, which are the intended cell substrate for vaccine
manufacture (Figure 2). At a multiplicity of infection of
0.01, rDEN1/4(CME) and rDEN1/4(ME) each reached a
virus titer of 7.3 log10 PFU/ml, which approximates the
yield of wild type DEN4 infection. Inclusion of the Δ30
mutation resulted in marginally reduced replication, but
even rDEN1/4Δ30(CME), which had the lowest level of
replication, reached a virus titer of 6.2 log10 PFU/ml. Thus,
after adaptation to growth in Vero cells, each chimeric
virus replicates to a level that would allow for efficient
manufacture of a vaccine virus.
Replication of chimeric viruses in SCID-HuH-7 mice
The level of replication of rDEN1/4 chimeric viruses was
first evaluated in SCID-HuH-7 mice since the level of rep-
lication in these mice is expected to correlate with the
level of attenuation in rhesus monkeys [7]. In this SCID
mouse model, tumors which develop from implanted
human hepatoma cells are infected with DEN viruses, and
viremia is assessed at seven days post-infection. Wild type
DEN4 has previously been shown to replicate to 6.0 log10
PFU/ml in SCID-HuH-7 mice [18]. Wild type DEN1
Puerto Rico/94 replicated to a mean peak virus titer of 6.6
log10 PFU/ml (Table 2), which is similar to replication lev-
els observed for the other wild type DEN viruses [11,12].
Replication of both CME chimeric viruses, rDEN1/
4(CME) and rDEN1/4Δ30(CME), was significantly
restricted when compared to the wild type DEN1 level of
replication with a 40-fold and 159-fold reduction in rep-
lication, respectively. The addition of the Δ30 mutation
did not appear to confer significant additional attenua-
tion upon the rDEN1/4(CME) chimeric virus.
In contrast, the rDEN1/4(ME) virus reached a peak virus
titer of 6.8 log10 PFU/ml and therefore, was not attenuated
for SCID-HuH-7 mice. rDEN1/4Δ30(ME) was signifi-
cantly restricted in replication compared to wild type
DEN1 with a 25-fold reduction in replication indicating
that the Δ30 mutation was attenuating when added to the
rDEN1/4(ME) virus. These results indicate that both the
Δ30 mutation and the virus origin of the C gene play a role
in the attenuation of rDEN1/4 viruses in SCID-HuH-7
mice.
Replication of chimeric viruses in rhesus monkeys
Wild type DEN1 Puerto Rico/94 was found to replicate
efficiently in rhesus monkeys comparable to previous
studies with the DEN1 Western Pacific strain [10]. All of
the animals infected with DEN1 Puerto Rico/94 devel-
oped viremia with a mean duration of 2.8 days and mean
peak virus titer of 2.0 log10 PFU/ml (Table 3). The rDEN1/
4(CME) virus appeared to be only marginally attenuated,
if at all, when compared to DEN1 Puerto Rico/94 in terms
of mean number of viremic days and mean peak virus
titer. However, rDEN1/4Δ30(CME) was found to be
attenuated when compared to wild type DEN1 virus and
the parent rDEN1/4(CME) virus. Viremia was detected in
only half of monkeys infected with rDEN1/4Δ30(CME),
and both the mean duration (0.5 days) and mean peak
virus titer (1.1 log10 PFU/ml) were less than that of both
wild type DEN1 and rDEN1/4(CME).
As had been observed in SCID-HuH-7 mice, infection of
rhesus monkeys with rDEN1/4(ME) yielded no evidence
of attenuation and the virus replicated to levels similar to
that of wild type DEN1. In contrast, replication of rDEN1/
4Δ30(ME) was found to be restricted when compared to
either wild type DEN1 or rDEN1/4(ME) and was similar
to that of rDEN1/4Δ30(CME). Fifty percent of monkeys
infected with rDEN1/4Δ30(ME) developed detectable
viremia. There was a four-fold reduction in the mean
duration of viremia (0.7 days) and nearly a ten-fold reduc-
tion in mean peak virus titer (1.1 log10 PFU/ml) compared
to wild type DEN1.
The level of serum neutralizing antibody titer was deter-
mined in monkeys 28 days post-immunization (Table 3).
Table 1: Nonsynonymous adventitious mutations identified in rDEN1/4 chimeric viruses after passage in Vero cells
Virus Gene/region Nucleotide Amino acid
Number1 Change Number2 Change
rDEN1/4(CME) NS4B 7134 A → G1 0 2 T h r  → Ala
NS4B 7156 U → C1 0 9 V a l  → Ala
rDEN1/4Δ30(CME) NS2B 4269 A → G4 5 S e r  → Gly
NS4B 7132 C → U1 0 1 P r o  → Leu
rDEN1/4(ME) NS4B 7162 U → C1 1 2 L e u  → Ser
rDEN1/4Δ30(ME) prM 603 C → G5 5 A r g  → Gly
NS4B 7182 G → C 119 Gly → Arg
3' UTR 10471 G insertion -- --
1 Nucleotide numbering is from 5' genome end.
2 Amino acid numbering is according to position in respective protein product.Virology Journal 2007, 4:23 http://www.virologyj.com/content/4/1/23
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Molecular construction of the DEN1 chimeric cDNA plasmids Figure 1
Molecular construction of the DEN1 chimeric cDNA plasmids. A. The CME structural protein coding region of the DEN4 
cDNA plasmid p4 was replaced with the corresponding region from DEN1 (Puerto Rico/94) CME sub-clone pUCBXR-init. Fol-
lowing introduction of a PstI site near the C-M junction of pUCBXR-init, the ME region of p4 was replaced with the corre-
sponding region from DEN1. Restriction sites used to facilitate the construction are indicated. The virus genomic regions for 
each of the resulting full-length chimeric cDNA plasmids are shown and the presence of the Δ30 mutation is indicated in the 3'-
UTR. DEN1 sequence is shaded. The resulting cloning junctions are numbered 1 – 5 and the inserted linker sequence is indi-
cated as a hatched box. The location of the linker is indicated. B. The nucleotide sequences surrounding the cloning junctions 
identified above are shown along with the predicted amino acid sequence corresponding to the virus polyprotein. Lower case 
letters indicate nucleotide substitutions that differ from wild type. For junction 3, the amino acid sequence is shown as pre-
dicted for the virus genome (with the linker sequence removed prior to transcription) and as predicted in E. coli where cryptic 
expression of the virus polyprotein with the linker sequence intact would result in translational termination. The termination 
codon in the polyprotein open reading frame that is located in the linker is indicated by * * *. Termination codons exist in the 
linker sequence for each of the additional forward and reverse open reading frames. For junction 4, the introduced PstI site is 
indicated. C = capsid protein; M = membrane protein (with precursor region), E = envelope protein; NS = nonstructural.
C M E NS1 NS2A NS2B NS3 NS4A NS4B NS5
p4 (DEN4) 3’ 5’
p4-D1L-CME 3’ 5’
Structural Non-structural
p4-D1-ME 3’ 5’
Δ30
p4Δ30-D1-ME 3’ 5’
Δ30
p4Δ30-D1L-CME 3’ 5’
Chimerization
13
4
Junction 5: -CTGCTGACATGGCTAGGATTAAACTCgAGGAACACTTCAATGGCTATGACG-
-LeuLeuThrTrpLeuGlyLeuAsnSerArgAsnThrSerMetAlaMetThr-
DEN1 DEN4 Xho I
Junction 2: -ATTATGAACAGGAGGAAAAAATCTGTGACCATGCTCCTCATGCTGCTGCCC-
-IleMetAsnArgArgLysLysSerValThrMetLeuLeuMetLeuLeuPro-
DEN1
Junction 1: -CAGTTTGTTTGAATAGAGAGCAGATCTCTGgaaaaATGAACAACCAACGG-
MetAsnAsnGlnArg-
DEN4 DEN1 Bgl II
A.
B.
Bgl II Xho I (Pst I)
2
Junction 4: -ATCTTGAACGGGAGAAAAAGGTCTGcagCCATGCTCCTCATGCTGCTGCCC-
-IleLeuAsnGlyArgLysArgSerAlaAlaMetLeuLeuMetLeuLeuPro-
DEN4 DEN1 Pst I
5
Junction 3: -CTAGGATTAAACTCgagtagactaagttaactacctcGAGGAACACTTCA-
-LeuGlyLeuAsnSer-----------------------ArgAsnThrSer-
-LeuGlyLeuAsnSerSerArgLeuSer***
DEN1 DEN4 Xho I
Linker
DEN1 subclone pUCBXR-init
Virus, no linker:
E. coli, with linker:
Xho I LinkerVirology Journal 2007, 4:23 http://www.virologyj.com/content/4/1/23
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Infection with wild type DEN1, rDEN1/4(CME), or
rDEN1/4(ME) resulted in 100% seroconversion, defined
as a four-fold or greater rise in serum neutralizing anti-
body levels after immunization. Neutralizing antibodies
were not detected in any of the four monkeys immunized
with rDEN1/4Δ30(CME) despite the presence of a low
level of viremia in two monkeys, suggesting that this
DEN1/4 chimeric virus may be over-attenuated. In con-
trast, four of six monkeys immunized with rDEN1/
4Δ30(ME) seroconverted with a geometric mean serum
neutralizing antibody titer of 1:23 which was approxi-
mately four-fold reduced from wild type DEN1 Puerto
Rico/94 (1:103).
All immunized monkeys were challenged with wild type
DEN1 virus on day 35 post-immunization and resulting
viremia was quantified (Table 3). Both mock-immunized
monkeys developed viremia after challenge with a mean
peak virus titer of 2.1 log10 PFU/ml. Prior immunization
with rDEN1/4(CME) induced complete protection from
detectable viremia after challenge. rDEN1/4Δ30(CME),
which was poorly immunogenic, failed to confer protec-
tion in three of four challenged monkeys. This result con-
firms the over-attenuation of the rDEN1/4Δ30(CME)
virus in rhesus monkeys. Both of the (ME) chimeric
viruses, rDEN1/4(ME) or rDEN1/4Δ30(ME), conferred
complete protection from viremia following wild type
DEN1 challenge including those animals that did not
develop detectable levels of serum antibody.
Replication of (ME) chimeric viruses in mosquitoes
Based on the high level of attenuation of rDEN1/
4Δ30(ME) virus in SCID-HuH-7 mice and in rhesus mon-
keys and on its protective efficacy in rhesus monkeys, it
appeared that this chimeric virus might be suitable for fur-
ther study in humans. Therefore, it was tested for infectiv-
ity and replication in Aedes aegypti mosquitoes to assess its
potential for transmissibility. The infectivity and level of
replication of rDEN1/4Δ30(ME) chimeric virus was com-
pared to those of wild type parental DEN1 and DEN4 and
of rDEN1/4(ME) following oral feeding of virus in a
bloodmeal. Specifically, following ingestion of an infec-
tious bloodmeal that contained 104.3 PFU/2 ul, virus rep-
lication in the midgut and dissemination to the salivary
glands was determined by plaque titration of virus in the
mosquito body and head, respectively. Wild type DEN1
and DEN4 replicated efficiently in the midgut of mosqui-
toes and dissemination to the salivary glands was robust
Table 2: rDEN1/4 chimeric virus replication in SCID-HuH-7 mice.
Virus1 No. mice Peak virus titer (log10 PFU/ml ± SE) Fold reduction from wild type DEN1
DEN1 Puerto Rico/942 18 6.6 ± 0.1 --
rDEN1/4(CME) 8 5.0 ± 0.43 40
rDEN1/4Δ30(CME) 7 4.4 ± 0.43 159
rDEN1/4(ME) 9 6.8 ± 0.3 -2
rDEN1/4Δ30(ME) 7 5.2 ± 0.53 25
1 Groups of SCID-HuH-7 mice were inoculated into the peritoneal tumor with 4.0 log10 PFU of the indicated virus. Serum was collected on day 7, 
and virus titer was determined in Vero cells.
2 Data combined from 2 experiments.
3 Significant reduction compared to wild type DEN1 (Tukey post-hoc test, P < 0.05).
Virus replication in Vero cells Figure 2
Virus replication in Vero cells. Virus titer in supernatants 
from infected cells was determined by plaque assay in Vero 
cells. The lower limit of detection was 0.7 log10 PFU/ml.
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with 88% and 71% of DEN1-infected or DEN4-infected
mosquitoes experiencing disseminated infections, respec-
tively (Table 4). 100% of mosquitoes with DEN1 midgut
infections developed disseminated infections, while 81%
of mosquitoes with DEN4 midgut infections had dissem-
inated infections. DEN1 reached mean virus titers that
were approximately 10-fold to 100-fold higher than
DEN4 in both the body and head. rDEN1/4(ME) virus
had slightly lower infectivity for the midgut, but dissemi-
nation to the head was comparable to that of its DEN4
wild type parent. The mean virus titer in the bodies (2.4
log10 PFU/body) or heads (3.0 log10 PFU/head) of rDEN1/
4(ME)-infected mosquitoes approximated the values
observed for wild type DEN4. However, presence of the
Δ30 mutation in rDEN1/4Δ30(ME) conferred a profound
reduction in mosquito infectivity. Virus infection was not
detected in the bodies (or heads) of the 24 mosquitoes
that were fed an infectious bloodmeal containing rDEN1/
4Δ30(ME) suggesting that the rDEN1/4Δ30(ME) chimeric
virus would be poorly transmissible by mosquitoes.
Discussion
Since the first report of the generation of an antigenic chi-
meric dengue virus using reverse genetics [19], numerous
viruses have been created using genes from tick-borne and
mosquito-borne flaviviruses, and many of these viruses
have potential usefulness as live attenuated virus vaccines
[15,20-25]. Recently, clinical studies have indicated that
antigenic chimeric flaviviruses may in fact be a safe and an
effective means of vaccination for protection against dis-
ease caused by the DEN viruses, Japanese encephalitis
virus (JEV), and West Nile virus (WNV) [16,26-28]. Spe-
cifically, the rDEN2/4Δ30(ME) vaccine candidate was
found to be safe in humans and induced a potent neutral-
izing antibody response against DEN2 [16]. In addition,
using the yellow fever virus 17D vaccine as the genetic
background, antigenic chimeric viruses expressing the M
and E genes of DEN2 [26], JEV [28], and WNV [27], have
been tested in humans and found to be safe and strongly
immunogenic. These promising clinical studies indicate
that continued development of antigenic chimeric flavivi-
ruses as live attenuated virus vaccines is a rational and
important pursuit. In the present study, an additional
antigenic chimeric virus, rDEN1/4Δ30(ME), is identified
that has an attenuation and immunogenicity phenotype
similar to the previously evaluated rDEN2/4Δ30(ME) and
rDEN3/4Δ30(ME) vaccine candidates [11,15]. Studies
were designed to assess the relative contribution of (1)
chimerization, (2) the parental origin of the C gene in the
DEN1/4 chimeric virus, and (3) the Δ30 mutation to the
attenuation of the DEN1/4 chimeric viruses for SCID-
HuH-7 mice, rhesus monkeys, and mosquitoes.
In previous studies, chimeric flaviviruses generated by
substitution of the ME proteins of a wild type flavivirus
such as WNV, Langat, DEN2 or DEN3, for the ME genes of
the DEN4 wild type virus, were uniformly attenuated for
rodents or rhesus monkeys [11,15,20,22]. This indicated
that chimerization resulted in attenuation of each chi-
meric flavivirus that was evaluated. Based on these obser-
vations, we fully expected that the rDEN1/4(ME) chimeric
virus generated in the present study would be attenuated
in SCID-HuH-7 mice or rhesus monkeys. However, this
was not observed. The rDEN1/4(ME) chimeric virus repli-
cated like parental wild type virus in SCID-HuH-7 mice,
rhesus monkeys, and mosquitoes. The ability of chimeri-
zation to attenuate rDEN2/4(ME) and rDEN3/4(ME), but
not rDEN1/4(ME), cannot be explained by differences in
the genetic relatedness among these viruses. The amino
acid homology of the DEN1, DEN2, and DEN3 structural
genes with those of DEN4 ranges from 63% to 67%. Since
the factors that control attenuation resulting from chimer-
Table 3: Replication and immunogenicity of rDEN1/4 chimeric viruses in rhesus monkeys.
Virus1 No. of 
monkeys
% of monkeys 
with viremia
Mean no. of 
viremic days 
per monkey
Mean peak virus titer2 
(log10 PFU/ml ± SE)
Geometric mean serum 
neutralizing antibody titer 
(reciprocal dilution)3
Post-challenge5
Day 0 Day 28 % sero-
conversion4
% of monkeys 
with viremia
Mean peak virus titer2 
(log10 PFU/ml ± SE)
DEN1 Puerto Rico/94 4 100 2.8 2.0 ± 0.1 < 5 103 100 0 < 1.0
rDEN1/4 (CME) 4 100 2.0 1.5 ± 0.1 < 5 56 100 0 < 1.0
rDEN1/4Δ30 (CME) 4 50 0.5 1.1 ± 0.1 < 5 < 5 0 75 1.7 ± 0.3
rDEN1/4 (ME) 4 100 4.0 2.1 ± 0.1 < 5 65 100 0 < 1.0
rDEN1/4Δ30 (ME) 6 50 0.7 1.1 ± 0.2 < 5 23 66 0 < 1.0
Mock infected 2 0 0 < 1.0 < 5 < 5 0 100 2.1 ± 0.2
1 Groups of rhesus monkeys were inoculated subcutaneously on day 0 with 5.0 log10 PFU of the indicated virus in a 1 ml dose. Serum was collected 
daily for 10 days to detect viremia and on day 28 for determination of neutralizing antibodies.
2 Virus titer in serum was determined by plaque assay in Vero cells.
3 Plaque reduction (60%) neutralizing antibody titers were determined using DEN1 Puerto Rico/94 as test virus.
4 Percentage of monkeys with a four-fold or greater rise in neutralizing antibody levels between day 0 and 28.
5 Monkeys were challenged after 35 days with DEN1 (Puerto Rico/94) administered subcutaneously in a 1 ml dose containing 5.0 log10 PFU. Serum 
was collected daily for 10 days to detect viremia.Virology Journal 2007, 4:23 http://www.virologyj.com/content/4/1/23
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ization have not been clearly identified, it would appear
that each antigenic chimeric virus that is generated will
need individual characterization to define the genetic fac-
tors contributing to its observed attenuation. In the case of
rDEN1/4(ME), chimerization does not result in attenua-
tion, and therefore attenuation of rDEN1/4(ME) chimeric
viruses must rely on genetic factors other than chimeriza-
tion itself.
The contribution of the parental origin of the C protein in
the DEN1/4 chimeric viruses to attenuation was assessed
by comparing the level of attenuation of rDEN1/4(ME)
and rDEN1/4(CME) in SCID-HuH-7 mice and rhesus
monkeys. Since rDEN1/4(ME) was not attenuated in
these animals, it was possible to determine whether the
parental origin of the C gene could influence the level of
replication in these hosts. It was previously found that
both rDEN2/4(CME) and rDEN2/4(ME) viruses resulted
in a similar level of attenuation in SCID-HuH-7 mice, rhe-
sus monkeys and mosquitoes indicating that the parental
origin of the C protein in the rDEN2/4 chimeric viruses
did not modify the level of attenuation resulting from chi-
merization [15]. Thus, a contribution of the C protein to
attenuation was not identified in the DEN2/4 chimeric
viruses. In the present study, rDEN1/4(CME), but not
rDEN1/4(ME) was significantly attenuated in SCID-HuH-
7 mice, but not in rhesus monkeys. In addition rDEN1/
4Δ30(CME) was more attenuated than rDEN1/4Δ30(ME)
in SCID-HuH-7 mice and rhesus monkeys. These findings
indicate that the presence of the DEN1 C protein in the
rDEN1/4(CME) and rDEN1/4Δ30(CME) had an inde-
pendent attenuating effect. Thus, the presence of a DEN1
C protein in a DEN4 backbone resulted in restricted repli-
cation, which was somewhat dependent upon the partic-
ular animal model and the presence or absence of the Δ30
mutation. It is not surprising that the presence of a heter-
ologous C gene might attenuate a chimeric DEN virus as
the C gene is known to be involved in packaging of the
RNA genome. The C gene has been shown to interact spe-
cifically with DEN virus RNA [29]. It is possible that this
interaction may be governed by serotype-specific interac-
tions which could explain why the CME chimeric virus
might be more attenuated than the ME chimeric virus.
Presence of the Δ30 deletion mutation in rDEN1/
4Δ30(ME) or rDEN1/4Δ30(CME) resulted in a restriction
of replication of the chimeric viruses for SCID-HuH-7
mice and rhesus monkeys indicating that this mutation
had a strong attenuating effect for each chimeric virus. In
the case of rDEN1/4Δ30(CME), the presence of the Δ30
mutation resulted in over-attenuation in rhesus monkeys.
This virus clearly had two factors contributing to attenua-
tion, namely, the Δ30 deletion mutation and the presence
of the DEN1 C gene. The over-attenuation of rDEN1/
4Δ30(CME) parallels what was observed for the rDEN2/
4Δ30(CME) virus where the presence of the Δ30 mutation
yielded a virus that did not infect rhesus monkeys, and
like the rDEN1/4Δ30(CME) virus, was over-attenuated for
rhesus monkeys [15]. The phenotype of rDEN1/
4Δ30(ME) indicated a strong effect of the Δ30 mutation
on attenuation since the rDEN1/4(ME) virus had no dis-
cernible level of attenuation. This is in contrast to the
studies of rDEN2/4Δ30(ME) and rDEN3/4Δ30(ME)
where inclusion of the Δ30 mutation did not appear to
augment the level of attenuation attributable to chimeri-
zation [11,15]. For these viruses, chimerization itself pro-
vided the dominant attenuating effect which may have
functionally masked the attenuation phenotype provided
by the Δ30 mutation.
The rDEN1/4Δ30(ME) virus has many properties that
make it an attractive vaccine candidate, and most of these
properties are shared by rDEN2/4Δ30(ME) and rDEN3/
4Δ30(ME) which are presently in clinical evaluation.
rDEN1/4Δ30(ME) was attenuated in SCID-HuH-7 mice
with a 25-fold reduction in replication compared to the
parental wild type DEN virus, and rDEN2/4Δ30(ME) and
rDEN3/4Δ30(ME) were similarly restricted in this host
[11,15]. In rhesus monkeys, infection with rDEN1/
4Δ30(ME) resulted in detectable viremia in 50% of mon-
Table 4: Replication of rDEN1/4(ME) chimeric viruses in Aedes aegypti
Virus1 No. mosquitoes Body2 Head2 % Dissemination3
% infected Mean virus titer 
(log10 PFU/body)
% infected Mean virus titer 
(log10 PFU/head)
DEN1 24 88 4.5 ± 0.1 88 4.7 ± 0.1 100
DEN4 24 88 3.0 ± 0.2 71 2.7 ± 0.3 81
rDEN1/4(ME) 24 63 2.4 ± 0.3 42 3.0 ± 0.4 67
rDEN1/4Δ30(ME) 24 0 < 0.4 0 < 0.4 0
1 Assuming a 2 ul bloodmeal, 4.3 log10 PFU virus of each virus were ingested.
2 Presence of virus in mosquito homogenates was determined by plaque assay in Vero cells. Mean virus titer was determined using values only from 
samples with detectable virus.
3 Calculated as no. infected heads/no. infected bodies.Virology Journal 2007, 4:23 http://www.virologyj.com/content/4/1/23
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keys, whereas 25% and 0% of rhesus monkeys infected
with rDEN2/4Δ30(ME) or rDEN3/4Δ30(ME) had
viremia, respectively [11,15]. Immunization with rDEN1/
4Δ30(ME) resulted in a mean number of viremic days of
less than one and a reduced mean peak virus titer com-
pared to the wild type parent virus, and these findings
were similar to those found with rDEN2/4Δ30(ME).
Immunization with rDEN1/4Δ30(ME), rDEN2/
4Δ30(ME), or rDEN3/4Δ30(ME) protected rhesus mon-
keys from challenge. Finally, replication of the chimeric
viruses was attenuated for Ae. aegypti mosquitoes indicat-
ing that each of the three antigenic chimeric viruses would
likely manifest decreased transmissibility by mosquitoes
[11,15]. These results indicate remarkably similar pheno-
types for these three viruses, suggesting that the three anti-
genic chimeric viruses could be combined with
rDEN4Δ30 to form a tetravalent formulation that may
exhibit balanced replication and immunogenicity. For a
tetravalent vaccine formulation, achieving a balance of
infectivity among the components is essential and has
proven in the past to be a difficult goal to achieve [30,31].
Where does the rDEN1/4Δ30(ME) virus fit into our over-
all plans to develop a tetravalent DEN virus vaccine? At
present, the rDEN1Δ30 virus, which contains the Δ30
mutation in the context of the full-length DEN1 genome,
appears to be our most promising DEN1 vaccine candi-
date for inclusion in a tetravalent formulation [10]. The
rDEN1Δ30 virus was found to be significantly attenuated
in SCID-HuH-7 mice and rhesus monkeys when tested as
a monovalent vaccine, and it was found to be an immu-
nogenic and protective component of a tetravalent vac-
cine formulation in rhesus monkeys [8,10]. In addition, a
recent phase I clinical trial in 20 volunteers indicated that
rDEN1Δ30 was safe and strongly immunogenic [14].
However, should the rDEN1Δ30 virus prove not to be a
suitable component of a tetravalent formulation when
tested in humans, the rDEN1/4Δ30(ME) vaccine candi-
date, described here, would be a reasonable back-up can-
didate based on its level of attenuation in SCID-HuH-7
mice, rhesus monkeys, and mosquitoes and its immuno-
genicity and protective efficacy in monkeys.
Conclusion
The construction of rDEN1/4 chimeric viruses with either
DEN1 CME or ME regions in the presence or absence of
the Δ30 mutation resulted in viruses with varying degrees
of attenuation in animal models and mosquitoes. These
results and our previous studies of chimeric DEN2/4 and
DEN3/4 viruses indicate that the degree of attenuation
conferred by the chimerization of flaviviruses can be
influenced by three factors: the serotype of the donor
structural genes, the constellation of the structural genes
(CME or ME), and the contribution of additional muta-
tions such as Δ30. Of the four DEN1 chimeric viruses eval-
uated in this study, rDEN1/4Δ30(ME) appears to have the
most promising preclinical phenotype, characterized by
attenuation in SCID-HuH-7 mice, rhesus monkeys, and
mosquitoes. The rDEN1/4Δ30(ME) vaccine candidate
appears to be suitable for evaluation in a clinical trial.
Methods
Cells and viruses
Vero cells (African green monkey kidney) were grown in
OptiPro SFM (Invitrogen, Grand Island, NY) supple-
mented with 4 mM L-glutamine (Invitrogen). HuH-7 cells
(human hepatoma) were maintained in D-MEM/F-12
(Invitrogen) supplemented with 10% fetal bovine serum
(FBS), 1 mM L-glutamine and 0.05 mg/ml gentamicin
(Invitrogen). C6/36 cells (Aedes albopictus mosquito) were
maintained at 32°C in Minimal Essential Medium (MEM)
containing Earle's salts and 25 mM HEPES buffer (Invitro-
gen) and were supplemented with 10% FBS, 2 mM L-
glutamine, and 0.1 mM non-essential amino acids (Invit-
rogen). The DEN1 Puerto Rico/94 virus was provided by
Dr. Duane Gubler (John A. Burns School of Medicine,
University of Hawaii).
Genetic construction of chimeric DEN1 viruses
Chimeric viruses have been generated in which the CME
and ME genes of the DEN4 p4 and p4Δ30 cDNA clones
have been replaced with the corresponding genes derived
from DEN1 Puerto Rico/94 (Figure 1). The genomic
region within nucleotides 72 – 2353 was amplified by RT-
PCR from the DEN1 Puerto Rico/94 genome using DNA
primers to introduce a single nucleotide change at 2344 to
create a translationally-silent XhoI restriction enzyme rec-
ognition site (Figure 1B). The resulting PCR fragment was
cloned blunt-ended into vector pCR2.1 (Invitrogen) from
which a 2255 bp fragment was obtained following partial
digestion with BglII (DEN1 nucleotide 86) and XhoI
(DEN1 nucleotide 2341). This 2255 bp fragment was
cloned into a modified pUC118 vector containing the AscI
– BglII fragment (SP6 promoter and DEN4 5'-UTR) from
plasmid p4 (GenBank Accession number, AY648301). To
generate a 5' untranslated region that would be identical
to that of DEN4, site-directed mutagenesis was used to
insert the nucleotides GAAAA immediately upstream of
the AUG initiation codon for the polyprotein (Figure 1B,
Junction 1), and the resulting plasmid was designated as
pUCBXR-init.
To generate full-length CME chimeric cDNA plasmids, the
AscI – XhoI region of p4 or p4Δ30 was replaced with the
corresponding fragment derived from DEN1 subclone
pUCBXR-init. Initially, ligation of the AscI – XhoI fragment
of pUCBXR-init into p4 or p4Δ30 failed to yield geneti-
cally stable full-length cDNA plasmids. However, ligation
in the presence of a synthetic DNA linker molecule con-
taining termination codons in each of the forward andVirology Journal 2007, 4:23 http://www.virologyj.com/content/4/1/23
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reverse coding frames and flanked by XhoI overhangs
yielded stable plasmids p4-D1L-CME and p4Δ30-D1L-
CME. The nucleotide and amino acid sequences of the
resulting junctions are shown in Figure 1B.
To generate ME chimeric cDNA plasmids, site-directed
mutagenesis of pUCBXR-init was used to introduce a
unique PstI restriction enzyme recognition site at DEN1
nucleotide 400 by substituting nucleotides 399–401
(UGA  → CAG) immediately downstream of coding
sequence for the trypsin cleavage site separating the C-
protein from its anchor region. Introduction of the PstI
cleavage site is translationally silent for the DEN4 portion
of the chimeric molecule; however, DEN1 C-protein
amino acids 102 – 103 are changed from Val – Thr to Ala
– Ala in the chimeric molecule (Figure 1B). A 1939 bp PstI
– XhoI fragment derived by partial digestion of the result-
ing plasmid was cloned into the PstI – XhoI window of a
pUC119 clone containing the AscI – XhoI region of DEN4
clone p4 to create plasmid pUC-D1(ME). To generate full-
length ME chimeric cDNA plasmids, the AscI – XhoI region
of p4 or p4Δ30 was replaced with the corresponding frag-
ment derived from DEN1 subclone pUC-D1(ME). The
resulting cDNA plasmids, p4-D1-ME and p4Δ30-D1-ME,
were genetically stable in E. coli and did not require the
XhoI synthetic linker fragment. The genomic region of
each chimeric cDNA was sequenced as previously
described [9] and GenBank accessions were assigned as
follows (plasmid: accession numbers): p4-D1L-CME:
EF456758, p4Δ30-D1L-CME: EF456759, p4-D1-ME:
EF456756, p4Δ30-D1-ME: EF456757.
Recovery and propagation of rDEN1 viruses
Plasmids were linearized with Acc65I (isoschizomer of
KpnI which cleaves leaving only a single 3' nucleotide),
and transcribed in vitro using SP6 polymerase. Prior to
linearization, the XhoI linker was excised from p4-D1L-
CME and p4Δ30-D1L-CME to restore the intact coding
sequence. Briefly, the p4-D1L-CME and p4Δ30-D1L-CME
plasmids were digested with XhoI and purified to remove
the short linker. The plasmids were then circularized by
DNA ligase and linearized by Acc65I.
Purified transcripts were transfected into Vero or C6/36
cells using DOTAP liposomes (Roche, Indianapolis, IN).
After recovery, viruses were passaged in Vero cells until
virus titers reached approximately 106 PFU/ml. Viruses
were subsequently biologically cloned by two or three ter-
minal dilutions before experimental stocks were grown in
Vero cells. The nucleotide sequence of each recovered
virus was determined as previously described [9].
For analysis of replication in tissue culture, confluent 75
cm2 flasks of Vero cells were infected with virus at a mul-
tiplicity of infection of 0.01. Aliquots of 0.5 ml were
removed from flasks daily for seven days. After addition of
SPG stabilizer (final concentration: 218 mM sucrose, 6
mM L-glutamic acid, 3.8 mM monobasic potassium phos-
phate, and 7.2 mM dibasic potassium phosphate, pH
7.2), samples were frozen on dry ice and stored at -80°C.
Virus titer was determined by plaque assay on Vero cells.
The limit of detection was 0.7 log10 PFU/ml.
Animal models of DEN virus infection
For analysis of virus replication in SCID-HuH-7 mice, four
to six week-old SCID mice (Tac:Icr:Ha(ICR)-Prkdcscid)
(Taconic, Germantown, NY) were injected intraperito-
neally with 0.1 mL phosphate-buffered saline containing
107 HuH-7 cells [32]. Five to six weeks after transplanta-
tion, tumor-bearing mice were infected by direct inocula-
tion into the tumor with 104 PFU of virus in 50 μl Opti-
MEM I (Invitrogen). Serum was collected from infected
mice on day 7 post-infection and frozen at -80°C. Virus
titer was determined by plaque assay in Vero cells [9].
DEN1 viruses were evaluated for replication and immu-
nogenicity in rhesus macaques using previously described
methods [9]. Dengue virus seronegative monkeys were
inoculated subcutaneously with 105 PFU of virus diluted
in L-15 medium (Invitrogen) or with a mock inoculum of
L-15 medium. Serum was collected on days 0–6, 8, 10 and
28 after inoculation and stored at -80°C. Virus titer in
serum was determined for each day by plaque assay in
Vero cells and serum neutralizing antibody titer was deter-
mined for days 0 and 28 by plaque reduction neutraliza-
tion test in Vero cells [9]. On day 35 post-infection, all
monkeys were challenged by subcutaneous infection with
105 PFU of DEN1 wild type virus. Serum was collected on
days 0–8 and on day 10 for virus titration and frozen at -
80°C.
Replication in mosquitoes
Virus replication was evaluated in Aedes aegypti provided
by Nancy McLean-Cooper (Walter Reed Army Institute for
Research). Mosquitoes were fed an infectious bloodmeal
and incubated for 21 days as previously described [33].
Assuming a 2 ul bloodmeal, 4.3 log10 PFU of virus was
ingested by the mosquitoes. After freezing, heads and
bodies were dissected and homogenized in 250 ul suspen-
sion buffer (Hank's balanced salt solution). Virus titer in
homogenates was determined by plaque assay in Vero
cells.
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